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The Women's Health Initiative (WHI) was the first randomized trial to assess the
overall risk and benefit of estrogen (0.625 mg/day conjugated equine estrogen) plus
progestin (2.5 mg/day medroxyprogesterone-acetate) (EP) in healthy postmenopausal
women with an intact uterus (1). The WHI designated invasive breast cancer as a primary
adverse outcome based on observational data (1) obtained from prior studies (2, 3). These
studies included a meta-analysis of estrogen replacement therapy's effect on breast
cancer risk that concluded by indicating a need to determine if breast cancer risk is
affected by progestin use (2) and another meta-analysis of estrogen and EP therapy which
concluded that the uncertainty of EP therapy's risk for breast cancer had not been studied
adequately (3).
The hormone replacement therapy (HRT) component of the WHI clinical trial
was designed to randomize 27,500 women for an average follow-up of approximately 9
years (4). Statistical stopping rules for the trial were determined by using hypothetical
sets of interim trial results (scenarios) after an average follow-up of6 years (5). Members
of the Data and Safety Monitoring Committee (DSMC) reviewed the scenarios and made
recommendations on whether or not to stop the trial (5).
The WHI trial was stopped early after an average follow-up of 5.2 years because
while the adverse effects of cardiovascular diseases remained within the monitoring
boundaries, the invasive breast cancer test statistic exceeded the adverse effect stopping
boundary and the risk exceeding the benefits was supported by the global index statistic
(defined as the earliest occurrence of coronary heart disease, stroke, pulmonary
embolism, invasive breast cancer, endometrial cancer, colorectal cancer, hip fracture, or
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death from other causes) (1). The trial found that among 10,000 women taking EP
compared with placebo, eight more might experience invasive breast cancers over a
I-year period, representing a 26% increase in breast cancer risk (1).
The WHI trial design was based on data available in 1991-1992 (1). Thus, we
perfonned a systematic review and meta-analysis of the available published studies on
the use of EP therapy and the risk of breast cancer in postmenopausal women that were
accepted for publication prior to the publication of the WHI's results (1) in July of2002.
Our analysis examines EP HRT and the risk of developing breast cancer associated with
ever, recent, or past, and never use ofEP HRT. International studies were not included in
the analysis since conjugated estrogens and medroxyprogesterone-acetate are primarily
used in the US, whereas in Europe, oestradiol combined with testosterone-like progestins
are commonly used (6). Our analysis of the literature detennines if more recent evidence
in the literature could have had implications in guiding the stopping rules of the WHI
trial.

Methods
Literature Search
We searched PubMed (National Library of Medicine and the National Institutes
of Health, Bethesda, MD) using combinations of keywords and some MeSH tenns for the
keywords postmenopausal, estrogen, oestrogen, progestin, honnone replacement therapy,
estrogen replacement therapy, oestrogen replacement therapy, breast cancer, and breast
neoplasms. Evidence Based Medicine (EBM) Reviews from the Cochrane Central
Register of Controlled Trials (CCTR) was searched using the keywords estrogen,
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progestin, postmenopausal (variations of the word), breast cancer, and breast neoplasms.
The American College of Physicians (ACP) Journal Club, Cochrane Database of
Systematic Reviews (CDSR), and the Database of Abstracts of Reviews of Effects
(DARE) from the EBM Reviews were searched using the keywords estrogen, progestin,
variations of the word postmenopausal, breast cancer, and breast neoplasms. We searched
the ACP Journal Club, CCTR, CDSR, DARE, and PubMed for meta-analyses or reviews
from 2001 through 2005 in an effort to find publications prior to the WHI trial results
published in 2002 that might be listed in the reference lists of these publications. We
reviewed all titles and abstracts identified by our searches and the reference lists of
relevant papers to broaden our search for additional articles.

Inclusion Criteria
Limits used for some of the searches included United States (US), clinical trial,
English, and human. Publications were eligible for inclusion in the analysis if they were
accepted for publication prior to the publication of the WHI's results (1) in July of2002,
if the incidence of breast cancer was reported in postmenopausal women who used EP
HRT, and if the study had a comparison group of never users (i.e., women who never
used any combination of estrogen or progestin HRT (e.g., estrogen only or EP HRT)).
Due to the limited availability of these published studies, we included studies into our
analysis regardless of the type or dosage of estrogen or progestin used, or the number of
days per month that progestin was used.
Studies limited to Canadian women were excluded from the analysis. However,
we did include one study in our analysis (7) that presented data from six US and one
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Canadian city. We included this study in our analysis since we had a limited number of
US studies and because Canadian data is often considered a proxy for US data.
We found that many of the papers that were eligible for inclusion in the analysis
covered the same cohort of women. For our analysis, we included the papers that reported
longer follow-up of the study cohort, more person-years of observation, a larger study
cohort, papers that placed more emphasis on EP HRT versus emphasis on other types of
HRT, or papers that placed an emphasis on breast cancers associated with the usage of
HRT rather than breast cancer associated with other risk factors (e.g., body mass index).

Data Abstraction
One author abstracted from each eligible study the first author's last name, year of
publication, the relative risk (RR) estimate (i.e., adjusted odds ratio (OR), relative odds
(RO), or relative risk), upper and lower 95% confidence intervals (CI), adjustments
(adjusted or unadjusted RR estimates), study type (case-control or cohort), exposure
(ever, recent, past), type of non-exposed subjects (never used any HRT, never used EP
HRT), race (all, White, Black, Hispanic, non-Hispanic), cancer type (where invasive was
defined as a minimum of 83% of cases included in the study were invasive, or the type of
cancer was not specified), time period of first cases of diagnosed breast cancer
(1960s-1970s, 1980s-1990s), and study location, included in the analysis since treatment
practices in different parts of the US may affect the estimates. We considered analyzing
breast cancer incidence versus mortality, but all eligible studies reported breast cancer
incidence, not breast cancer mortality, therefore we were not able to compare incidence
versus mortality. We defined recent use ofEP therapy as use within the last 2 years
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immediately prior to the reference date and past use as use ofEP >2 years ago. Ever use
was defined as recent plus past use.
Four slight variations to our categorization of use included 1) the recent use data
in the Schairer (8) study which provided an adjusted estimate for current users, not
including use in the past 1-2 years, 2) the past use data in the Schairer (8) study which
included data from 1-2 years, 3) the Newcomb (9) study in the past/never use analysis
where past included use <5 years ago but separated out the current users, and 4) the Ross
(10) study in the past/never use analysis which ascertained exposure histories up to one
year before the reference date.
There were two ways of classifying study locale, one for the ever/never results
and one for the recent/never results, because all of the studies in the ever/never and
recent/never analyses could not be grouped into a single type of locale descriptor that was
suitable for all study locations. In the ever/never studies, Eastern US was defined as
studies done in Eastern or Central time zones, and Western US was defined as studies
that had some sites in the Western part as well as across the US. The recent/never studies
were categorized according to studies conducted in one or two time zones in the US, or
studies representative of cities across the US and/or one city in Canada. We were not able
to classify study local for the past/never studies into two distinct study local descriptors
that were suitable for all study locations due to the limited number of studies in this
analysis.
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Statistical Analysis
Meta-analyses of three groupings of the published studies were performed: 1)
ever/never EP HRT use, 2) recent/never EP HRT use, and 3) past/never EP HRT use. We
categorized never use ofEP HRT into two categories: 1) women who never used any
combination of estrogen or progestin HRT (i.e., estrogen only or EP HRT) during their
lifetime, and 2) women who never used EP HRT (i.e., combined estrogen and progestin
HRT). Some of the studies were used in more than one analysis because results within the
particular study were categorized according to more than one of the three types of use
(i.e., ever, recent, past).
STATA Version 9.1 (Stata Corp., College Station, TX) was used to analyze the
effect of EP HRT on the risk of breast cancer in postmenopausal women. The published
studies reported ORs, RRs, or ROs for case-control studies and RRs for cohort studies,
unless they reported only patient years of observation. We report all published ORs as
RRs since the risk ratio and rate ratio are approximately equal over the follow-up period
when the outcome is rare (11).
We always abstracted adjusted RR estimates wherever they were available and
made sure that they were properly adjusted for potential confounders. When adjusted
estimates were not available, we computed unadjusted estimates ourselves using either
Episheet (12), or the "metan" command in Stata when risk ratios, rather than rates or
hazards, were reported in the published paper.
We generated forest plots and used the "metabias" command in Stata as an
indication of the potential for publication bias. We produced funnel plots and looked for
evidence of funnel plot asymmetry visually and with the Begg and Mazumdar test (13),
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the Egger et al. test (14), and the Duval and Tweedie trim and fill imputation method
(15). We assessed overall heterogeneity of the literature by examining Cochrane Q P
values from the "meta" analysis in Stata.
We examined studies for heterogeneity with regard to specific study
characteristics by performing stratified and random effects meta-regression (16) analyses
using the restricted maximum likelihood method to estimate the among study variance.
Associations between RR estimates and characteristics of studies and patients were
analyzed. We inferred the standard errors of the log RR estimates from their 95%
confidence intervals (17).
Multi-variable meta-regression was not possible due to the small number of
studies. All meta-regression results were transformed back to the original ratio scale.
After transformation, each meta-regression coefficient estimated the ratio of the average
RR in studies with one characteristic to the average RR in studies with another
characteristic. These models quantified the degree of association between study
characteristics and results.
Study characteristics analyzed included adjustments, type of study, time of
diagnosis, type of cancer, and study location in the ever/never analysis; and study type,
time of diagnosis, and study location in the recent/never analysis. Meta-regression
analyses were conducted only when there were at least two studies in each category of a
study characteristic.
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Results

Of the ten eligible studies (7-10, 18-23) that met the inclusion criteria for the
analysis (Table 1), six, five, and three studies were included in the ever/never,
recent/never, and past/never analyses, respectively. One study (i.e., Li et al. (24)) was
excluded from our analysis since it was the only study that presented results according to
never use of the combined EP HRT regimen.
Adjusted RR estimates were used for all analyses with the exception of the
Gambrell study (18) in the ever/never analysis, and the Newcomb (9), Ross (10), and
Schairer (8) studies in the past/never analysis, where only unadjusted RR estimates were
available by using our calculations. We estimated the 22-year risk ratio from the one
cohort study by Nachtigall (20). The characteristics of the individual studies and the
analysis that they were used in are presented in Table 1.

Ever/Never Use
Four of the six estimates are below the null value in the direction of a reduced rate
of breast cancer among EP users. Nachtigall (20) is by far the least precise estimate (i.e.,
furthest away from the null) (Figure 1). Some of these estimates are much more (and less)
imprecise than others. The three least precise estimates are below the null and the three
very precise estimates are close to the null. The estimate we computed from N achitgall' s
study (20) is an exceedingly imprecise estimate. Inconsistent study results indicate
heterogeneity .
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Evidence of asymmetry was observed in the funnel plot, however some of the
estimates were computed and are imprecise. The Begg and Egger tests (13, 14) both gave
P=0.02, indicating evidence of funnel plot asymmetry, but the trim and fill analysis (15)
imputed no hypothetically missing studies. The overall heterogeneity value ofP=O.OOI
is indicative of a very heterogeneous literature.
Fixed and random summary effects estimates are likely to be different due to
imprecise estimates. Fixed stratified results are reported for most study characteristics,
however random stratified results are reported for the study type, time of diagnosis, and
study location study characteristics. Study characteristic analyses (Table 2) that included
studies that were adjusted, specified invasive breast cancer, and had sites in the Western
US as study characteristics suggest an increased risk of breast cancer of22%, 22%, and
10%, respectively among ever users ofEP HRT. These study characteristics gave higher
summary RRs on average than the study characteristics of study sites that gave
unadjusted RR estimates, did not specifY the type of breast cancer, and were conducted in
the Eastern US. When the unadjusted RR estimates, non-specified types of breast cancer,
and studies conducted in the Eastern US were removed from the analysis, the summary
RR indicated increased risks of breast cancer among women who ever used EP HRT. All
95% CIs for summary RR estimates were wide. Our analysis suggests that the risk of
developing breast cancer in women that ever used EP HRT was decreased in studies that
reported unadjusted RR estimates, did not specifY the type of breast cancer, or had sites
only in the Eastern part of the US by 82%,82%, and 53% respectively.
The risk of developing breast cancer was negligible (1 %) in case-control studies
and in studies with cases first diagnosed in the 1980s and 1990s. The risk of developing

9

breast cancer was increased in studies with adjusted RRs, case control studies, first cases
of breast cancer diagnosed during the 1980s and 1990s, invasive breast, and studies that
included results from states in the Western part of the US. These study characteristics
increase the risk of developing breast cancer by 6YS, 2YS, 2YS, 6YS, and >2 times,
respectively. A modest increase in the risk of developing breast cancer was observed in
studies with unadjusted RRs, cohort studies, first cases of breast cancer diagnosed during
the 1960s and 1970s, unspecified types of cancer, and studies that included results from
states in the Eastern part of the US. All 95% CIs for the ratio ofRR estimates were wide.
The homogeneity P values for the unadjusted studies and the studies with
unspecified types of cancer were >0.2. This suggests homogeneity amongst the studies
and that the studies do not differ a lot due to chance. The low P values (P<0.2) for all
other study characteristics tested suggest heterogeneity amongst the studies and
inconsistency due to chance.
There is a lot of overall heterogeneity and several study characteristics have
strong, but imprecise associations with study results. The funnel plot asymmetry mayor
may not be due to biased literature; or the asymmetry may be due to one or more
characteristics of studies that produce less precise estimates compared to studies that give
more precise estimates. The study characteristics analysis lends support to the latter
reason since it is hard to calculate estimates (i.e., Nachtigall (20), Gambrell (18)) and
these values were further away from the null. Since the results were further away from
the null and not reported by the authors, this is opposite of what we would expect if there
was evidence of publication bias. In addition, two of the three imprecise and inverse
associations (i.e., Nachtigall (20), Gambrell (18)) were unadjusted and did not specify the
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type of cancer, therefore this analysis relies on the three more precise studies and all three
are near the null. As a result, a single point summary estimate of this literature is
contraindicated. Essentially, any study characteristic that separates two or all three of
Nachtigall (20), Moorman (19), and Gambrell (18) from the others is going to show an
association with an increased risk of breast cancer.

Recent/Never Use
All five estimates are above the null value in the direction of an increased rate of
breast cancer among EP users (Figure 1). Some of these estimates are much more or less
imprecise than others, with Kaufman (7) as the least precise estimate. Estimates from the
three largest studies were more precise. These results indicate some homogeneity
amongst the three largest studies.
Evidence of asymmetry was observed in the funnel plot. There was also some
evidence of funnel plot asymmetry with Begg (13) and Egger (14) P values of 0.2 and
0.02, respectively. In addition, the trim and fill analysis (15) did impute one small,
hypothetically missing study. However, the overall heterogeneity P value of 1.0 is
indicative of a more homogeneous body of literature.
Fixed and random summary effect estimates are likely to be similar due to a more
homogeneous literature, thus fixed stratified results are reported for all study
characteristics. Study characteristic analyses (Table 2) resulted in all examined study
characteristics giving approximately the same summary RR. All 95% CIs for summary
RR estimates were wide. All ratios ofRR estimates were 1.0, indicating an approximately
identical probability of disease in women who were recently exposed and not exposed to
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EP HRT. All study characteristic homogeneity P values were greater than 0.2, suggesting
homogeneity amongst the studies and that the studies do not differ a lot due to chance.
We did not perform a study characteristic analysis for the type of cancer study
characteristic due to the lack of available studies for this study characteristic.
Our analysis showed that there was not nearly as much overall heterogeneity to
begin with, and none of the study characteristics were associated with the results. Overall,
there was evidence of a symmetrical funnel plot, homogeneity P values were high, and all
RR were equal to 1.0, warranting a summary estimate. The summary RR estimate for the
recent-never results was 1.42 (95% cr, 1.26-1.60) representing a 40% increase in the risk
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of breast cancer among women who recently used EP HRT. This estimate was similar to
the trim and fill estimate of 1.41 (95% cr 1.25-1.59).

Past/Never Use
All three estimates are above the null value in the direction of an increased rate of
breast cancer among EP users (Figure 1). All estimates were computed, and some of
these estimates are much more (and less) imprecise than others, with the Newcomb (9)
estimate being the least precise estimate. Inconsistent study results are indicative of a
heterogeneous literature.
Evidence of asymmetry was observed in the funnel plot. Begg (13) and Egger
(14) P values were 0.3 and 0.6, respectively and suggest funnel plot symmetry. The trim
and fill method (15) imputed no hypothetically missing studies. The overall heterogeneity
P value of 0.1 is indicative of heterogeneous literature.
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Due to the limited number of studies in this analysis, study characteristics
analyses were not performed and a single summary estimate was contraindicated.

Discussion
This systematic review suggests that there was limited information about the risk
ofEP HRT and the risk of breast cancer in postmenopausal North American women prior
to the publication of the WHI trial results. This analysis of the ten observational studies
conducted prior to the publication of the WHI results suggest that there was consistent
evidence of increased risk from using these preparations recently, as opposed to never,
and inconsistent results for ever use, with the most precise estimates being very close to
the null.
Limitations of our analysis include restricting our analysis to studies accepted for
publication prior to the publication of the WHI's results (1) in July of 2002, including
only studies conducted in the US, not considering dosages or types ofEP HRT used in
the studies, and the limited number of studies available for our analysis.
We decided early in our analysis not to summarize the data into a single point
summary estimate due to the limited amount of data and the difficulty assessing it for
evidence of publication bias. Overall heterogeneity P values for the ever/never and the
past/never analysis are suggestive of a heterogeneous body of literature, whereas the P
value for the recent/never analysis was suggestive of a more homogeneous body of
literature. As a result we decided after our analysis of the literature that a summary
estimate was warranted for the recent/never analysis
We could not pin down the heterogeneity of the ever/never results to a single
study characteristic. Every one we looked at had some kind of association with the
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studies' results and there is not much more that can be done with only six studies. For the
recent/never analysis, there was not much evidence of heterogeneity to begin with and the
associations with all the study characteristics were about as null as they could be
expected to be in such a small number of studies.
The WHI trial (1) reported a 26% increase in invasive breast cancer and suggested
that the increased risk was consistent with the nonsignificant 27% increase reported after
6.8 years of follow-up in the HERS study (25). The HERS study was not included in our
meta-analysis. The WHI findings are consistent with other epidemiological data (26) that
reported a 15% increase of breast cancer when EP was used <5 years and a 53% increase
for use >5 years and our analysis that reports a 40% increase in the risk of breast cancer
among recent users of EP HRT.

Lack of evidence (2) and inconsistencies in the data (3) prevented calculation of a
summary estimate in prior meta-analyses conducted in the early 1990s. However, the
literature published through mid-2002, combined with different methodological
techniques used in our analysis, allowed for a single summary estimate of the literature
for recent EP HRT use. Our findings indicate that the literature in the early 1990s looks
very different from the literature in mid-2002.

Our ever/never and recent/never analysis results look different. Including past use
in the ever use category may have diluted out the recent use. Past exposure is less
relevant to risk and may result in misclassification of exposure. This may explain why
there was no association amongst the three largest studies in the ever/never analysis and
why there was a consistent, appreciable increase in risk in the recent/never analysis. Our
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analysis of the literature resulted in a 40% relative increase in breast cancer in women
that used EP HRT. This represents an absolute increase in risk of approximately 5% (27).
Our findings do not imply that the stopping rules of the WHI trial (1) should have
been changed based on the literature available in mid-2002, especially since the stopping
rule that our analysis suggests is less conservative than the stopping rules that were
applied during the trial. In addition, our analysis had limitations, thus we conclude that
the WHI trial (1) was a very important trial to conduct since it was the first randomized
controlled trial designed to assess the risk and benefit of EP HRT as opposed to using
observational data and because it represented a larger cohort of postmenopausal women.
The findings from the WHI should continue to inform relevant postmenopausal hormone
therapy treatment options for women.
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Table 1: Characteristics of Studies Containing Estimates of Breast Cancer Relative Risks According to the Use of Estrogen
and Progestin Postmenopausal Hormone Replacement Therapy
Analysis
EverlNever

Gambrell (18)

Publication
Year
1986

Study Design
Cohort

Adjustment
No

RR

95%CI

Cancer Type

0.19 0.09-0.40 Not specified

Time of
Diagnosis

Location

1960s & 1970s Eastern USb

Invasivea

1980s & 1990s Eastern USb

Moorman (19)

2000

Case-control

Yes

0.70

0.40-1.1

Nachtigall (20)

1992

Cohort

No

0.04

0-0.68

Not specified

Newcomb (9)

2002

Case-control

Yes

1.4

1.2-1. 7

Invasive

1960s & 1970s Eastern USb
1980s & 1990s Eastern USb

Schairer (8)

2000

Cohort

Yes

1.3

1.0-1.6

Invasive

1960s & 1970s Western USc

Stanford (21 )
Chen (22)

1995
2002

Case-control
Case-control

Yes
Yes

0.90
1.5

0.70-1.3 Invasive
1.0-2.1 Invasive

Colditz (23)

1995

Cohort

Yes

1.4

1980s & 1990s Western USc
1980s & 1990s 1-2 US time
zones
1960s & 1970s Across US

Kaufman (7)
Newcomb (9)

1991
2002

Case-control
Case-control

Yes
Yes

1.7
1.4

0.90-3.6 Not specified
1.1-1.7 Invasive

Cohort
Schairer (8)
2000
Case-control
PastlNever
Newcomb (9)
2002
Case-contro I
2000
Ross (10)
Cohort
2000
Schairer (8)
a Where at least 83-89% of the cases were invasive.
b Studies done in Eastern and Central time zones
C Studies that have some sites in the Western part of the US.
d Included the Canadian city of London, Ontario.
Abbreviations: NA, not applicable; US, United States
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No
No

1.4
1.9
1.2

1.1-1.9
1.2-3.2
0.99-1.4
0.73-1. 7

RecentlNever
>-'

First Author

1.2-1. 7

Invasive

\0

1.1

Invasive
Invasive
Invasive
Invasive

1980s & 1990s Across USd
1980s & 1990s 1-2 US time
zones
1960s & 1970s Across US
1980s & 1990s NA
1980s & 1990s NA
1960s & 1970s NA

Figure 1: Forest Plots of EverlNever, RecentlNever, and PastlNever
Meta-Analyses
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Table 2. Analysis of Study Characteristics
Analysis
Study
characteristic Design
EverlNever
Adjustment
Unadjusted
Adjusted

Number of
studies
2
4

Homogeneity
P-value
0.28
0.01

SummaryRR
{95% CI}
0.18 (0.09 - 0.36)
1.22 (1.07 - 1.39)

Ratio ofRRs
{95% CI}
1.0
6.5 (2.6-15.9)

Study design

Cohort
Case control

3
3

0.00
0.01

0.31 (0.05-1.79)
1.01 (0.66-1.54)

1.0
2.5 (0.6-10.9)

Time of
diagnosis

1960s-1970s
1980s-1990s

3
3

0.00
0.01

0.31 (0.05-1.79)
1.01 (0.66-1.54)

1.0
2.5 (0.6-10.9)

Cancer type

Not specified
>83% of cases were invasive

2
4

0.28
0.01

0.18 (0.09-0.36)
1.22 (1.07-1.39)

1.0
6.5 (2.6-15.9)

Location

Eastern US
Western USa

4
2

0.00
0.06

0.47 (0.16-1.33)
1.10 (0.77-1.57)

1.0
2.2 (0.5-10.0)

Study design

Cohort
Case control

2
3

0.97
0.84

1.41 (1.19-1.66)
1.43 (1.20-1.71)

1.0
1.0 (0.8-1.3)

Time of
diagnosis

1960s-1970s
1980s-1990s

2
3

0.97
0.84

1.41 (1.19-1.66)
1.43 (1.20-1.71)

1.0
1.0 (0.8-1.3)

Location

1-2 times zones in US
Across USb

2
3

0.74
0.87

1.41 (1.18-1.70)
1.42 (1.21-1.67)

1.0
1.0 (0.8-1.3)

N

......

RecentlNever

a Includes some studies conducted throughout the United States involving some Western states.
b One study included the Canadian city of London, Ontario.
Abbreviations: CI, confidence limits; RR, relative risk; NA, not applicable; US, United States.

